Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice in Patients with Venous Thromboembolism in Europe

Data inizio
14 dicembre 2016
Durata (mesi) 
Ingegneria per la medicina di innovazione
Responsabili (o referenti locali)
Lippi Giuseppe

Edoxaban is an orally administered anticoagulant that inhibits coagulation factor Xa. It has recently been approved by the European Medicines Agency EMA for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, as well as for the treatment of adult patients with venous thromboembolism including deep vein thrombosis and/or pulmonary embolism (after initial heparin lead-in), and the prevention of recurrent VTE.
This study aims to gather further insight into efficacy (i.e. symptomatic recurrent VTE) and safety (i.e. bleeding events, liver adverse events and other drug related adverse events) of the treatment with Edoxaban in an unselected patient population in routine clinical practice. Real worls evidence data of routine clinical practice use of Edoxaban up to 18 months will be collected in 2550 patients, treated by specialized as well as non-specialized physicians in hospitals and office based centres.

Enti finanziatori:

Finanziamento: assegnato e gestito da un ente esterno all'ateneo

Partecipanti al progetto

Giuseppe Lippi
Professore ordinario

Collaboratori esterni

Roberto Facchinetti
Azienda Ospedaliera Universitaria Integrata di Verona